17-AAG Induces Endoplasmic Reticulum Stress-mediated Apoptosis in Breast Cancer Cells, Possibly Through PERK/eIF2α Up-regulation
Open Access
- 26 August 2024
- journal article
- research article
- Published by International Institute of Anticancer Research in In Vivo
- Vol. 38 (5) , 2228-2238
Abstract
Background/Aim: Breast cancer is the most predominant type of cancer affecting women worldwide and the current therapeutic treatment for breast cancer patients is not adequately effective. This study aimed to investigate the mechanism of 17-AAG, a heat shock protein (HSP90) inhibitor, as a treatment for inducing breast cancer cell apoptosis. Materials and Methods: The pharmacology network was employed to examine the correlation of 17-AAG with the gene expression profiles of breast cancer, obtained by Gene Expression Profiling Interactive Analysis (GEPIA). MTT and flow cytometry were utilized to investigate cell proliferation and cell apoptosis, respectively. Dichloro-dihydro-fluorescein diacetate (DCFH-DA) assay and western blot analysis were employed to examine the correlation between cellular oxidant levels and protein expression. Immunofluorescence staining was utilized to confirm the protein localization and assess DNA damage. Results: The pharmacological network analysis revealed that HSP90 serves as the common target connecting 17-AAG and breast cancer genes. Treatment with 17-AAG significantly increased cell apoptosis. Moreover, the treatment resulted in up-regulation of cellular oxidant levels and PERK/eIF2α expression. In line with these, protein localization after treatment revealed an increase in DNA damage, correlating with higher ER stress levels. Furthermore, GEPIA demonstrated that PERK and eIF2α expression were significantly higher in breast invasive carcinoma compared to other tumor types. Conclusion: HSP90 emerges as a potential target for inducing apoptosis in breast cancer cells by disrupting protein homeostasis in the endoplasmic reticulum, possibly through PERK/eIF2α up-regulation. 17-AAG, an HSP90 inhibitor, may therefore potentially hold an alternative therapeutic strategy for breast cancer treatment.Keywords
This publication has 28 references indexed in Scilit:
- Endoplasmic reticulum stress inhibits AR expression via the PERK/eIF2α/ATF4 pathway in luminal androgen receptor triple-negative breast cancer and prostate cancernpj Breast Cancer, 2022
- The unfolded protein response as regulator of cancer stemness and differentiation: Mechanisms and implications for cancer therapyBiochemical Pharmacology, 2021
- Endoplasmic reticulum stress signals in the tumour and its microenvironmentNature Reviews Cancer, 2020
- Crosstalk between endoplasmic reticulum stress and oxidative stress in the progression of diabetic nephropathyCell Stress and Chaperones, 2020
- RETRACTED: Novel C‐terminal heat shock protein 90 inhibitors target breast cancer stem cells and block migration, self‐renewal, and epithelial–mesenchymal transitionMolecular Oncology, 2020
- Endoplasmic Reticulum Stress Signaling in Cancer CellsThe American Journal of Pathology, 2020
- The HSP90/Akt pathway may mediate artemether‐induced apoptosis of Cal27 cellsFEBS Open Bio, 2019
- Knockdown of TM9SF4 boosts ER stress to trigger cell death of chemoresistant breast cancer cellsOncogene, 2019
- A phase II study of 17-allylamino-17-demethoxygeldanamycin in metastatic or locally advanced, unresectable breast cancerBreast Cancer Research and Treatment, 2011
- PERK promotes cancer cell proliferation and tumor growth by limiting oxidative DNA damageOncogene, 2010